Most popular posts
- What makes great boards great
- The fate of control
- March Madness and the availability heuristic
- When business promotes honesty
- Due diligence: mine, yours, and ours
- Alligator Alley and the Flagler (?!) Dolphins
- Untangling skill and luck in sports
- The Southeastern Growth Corridors
- Dead cats and iterative collaboration
- Empirical evidence: power corrupts?
- A startup culture poses unique ethical challenges
- Warren Buffett and after-tax returns
- Is the secret to national prosperity large corporations or start-ups?
- This is the disclosure gap worrying the SEC?
- "We challenged the dogma, and it was incorrect"
- Our column in the Tampa Bay Business Journal
- Our letter in the Wall Street Journal
Other sites we recommend
Monthly Archives: May 2022
YPrime Announces Additions to Executive Team
YPrime, LLC, a global leader in cloud-based eClinical solutions, announces the addition of two key members to its executive team—Mohan Ganesan, Chief Financial Officer and Alison O’Neill, Chief Operating Officer.
As chief financial officer, Mohan Ganesan provides financial and strategic guidance to the company and partners with our investors and executive team to drive investments appropriately. Mohan provides financial oversight and leads the development of standardized business metrics for finance, accounting, business operations, and human resource functions.
As chief operating officer, Alison O’Neill oversees the departments responsible for project management and quality delivery of YPrime’s products and services. With more than 35 years of clinical research experience beginning as a bench chemist in the pharmaceutical industry, Ali has held executive roles in global organizations providing technology solutions to the industry.
“It’s a real privilege to add these two experienced leaders to our executive team,” says Shawn Blackburn, CEO, YPrime. “We have always been about ensuring an optimal experience for sponsors, sites, and patients. Under Mohan’s leadership, we will be able to make strategic decisions about investments that will serve our clients’ ever-evolving needs and measure the impact of our business. Ali’s depth of expertise allows us to continue enhancing our products, processes, and services to meet the needs of these crucial stakeholders throughout a clinical trial.”
